Viemed Healthcare AI Stock Analysis
Want to see VMD full AI Analyst Report?
Viemed Healthcare (VMD) AI Stock Analysis
Viemed Healthcare
(NASDAQ:VMD)
Viemed Healthcare's overall score of 65 reflects a company with a strong financial foundation and positive operational momentum, offset by profitability and cash flow challenges. The most significant positive factors are the fortress-like balance sheet and the constructive earnings call, which highlighted record revenue, raised guidance, and clear growth catalysts in sleep and maternal health. Technical trends are also supportive. However, these strengths are weighed down by a weak cash flow profile, compressing margins, and a dramatic slowdown in revenue growth, which introduce financial risk. The moderate P/E ratio and lack of a dividend further temper the overall score.
Viemed Healthcare (VMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $347.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 273.48K
- Price to Earnings (P/E)
- 22.5
- Beta (1Y)
- 0.47
- Revenue Growth
- 21.81%
- EPS Growth
- 17.67%
- Country
- US
- Employees
- 1,490
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Viemed Healthcare Business Overview & Revenue Model
Company Description
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chroni...
How the Company Makes Money
Viemed primarily makes money by providing home-based respiratory therapy solutions that combine durable medical equipment (DME) with ongoing clinical and support services, and then billing third-party payors for those products and services. Its core...
Viemed Healthcare Earnings Call Summary
The call was broadly positive, led by record revenue, double-digit organic growth, strong net income and adjusted EBITDA expansion, growing sleep and maternal health volumes, improving ventilation revenue, capital returns, and higher revenue guidance. The primary challenges were slightly lower gross margin, increased audit-related work and payment timing, temporarily weaker cash conversion, volatility in ventilation active patients, and a lower upper end to adjusted EBITDA guidance.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management now expects full-year revenue of $316 million to $320 million, compared with the previous range of $314 million to $320 million; adjusted EBITDA guidance is $64 million to $66 million, compared with the previous range of $64 million to $68 million; and net CapEx is expected to be 8% to 9% of revenue, compared with 8.5% to 10% previously. The revised outlook anticipates sequential growth in both revenue and adjusted EBITDA in the fourth quarter and excludes any potential future acquisitions or strategic transactions. Viemed is on track to enter 2 additional states per quarter beginning in the fourth quarter for maternal health, expects ventilator active patient count to be back up in the fourth quarter, and expects to stay up in the 20-plus percent adjusted EBITDA for the time being.
Viemed Healthcare Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is a key strength with very low debt (D/E 0.06) and a healthy ROE of 10.3%. However, this is offset by deteriorating income trends, including a sharp revenue growth deceleration to 2.9% TTM and compressing net margins to 5.0%. Cash flow is a significant weakness, with volatile and declining free cash flow, indicating poor conversion of profits.
Income Statement
62PositiveBalance Sheet
78PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 310.37M | 270.28M | 224.26M | 183.01M | 138.83M | 117.06M |
| Gross Profit | 177.39M | 155.46M | 133.20M | 112.78M | 84.68M | 73.41M |
| EBITDA | 47.79M | 51.56M | 42.31M | 36.68M | 24.82M | 24.13M |
| Net Income | 15.62M | 14.93M | 11.27M | 10.24M | 6.22M | 9.13M |
Balance Sheet | ||||||
| Total Assets | 207.63M | 199.15M | 177.07M | 154.90M | 117.04M | 117.96M |
| Cash, Cash Equivalents and Short-Term Investments | 9.68M | 13.50M | 17.54M | 12.84M | 16.91M | 28.41M |
| Total Debt | 9.28M | 15.95M | 6.87M | 10.32M | 694.00K | 6.52M |
| Total Liabilities | 55.65M | 55.63M | 43.77M | 41.00M | 19.95M | 23.14M |
| Stockholders Equity | 150.09M | 141.54M | 131.39M | 113.89M | 97.09M | 94.82M |
Cash Flow | ||||||
| Free Cash Flow | 21.38M | 11.93M | 1.32M | 19.12M | 4.85M | 2.75M |
| Operating Cash Flow | 53.90M | 51.92M | 39.09M | 45.21M | 27.75M | 22.49M |
| Investing Cash Flow | -28.40M | -50.17M | -30.70M | -52.11M | -23.98M | -19.75M |
| Financing Cash Flow | -26.95M | -5.79M | -3.69M | 2.83M | -15.27M | -5.32M |
Viemed Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Negative. The current price of 9.17 is below the 20-day moving average (MA) of 9.52, below the 50-day MA of 9.28, and below the 200-day MA of 9.66, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 29.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VMD.
Viemed Healthcare Risk Analysis
Viemed Healthcare disclosed 39 risk factors in its most recent earnings report. Viemed Healthcare reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksViemed Healthcare Peers Comparison
Overall Rating
TCMD75Outperform
BVS66Neutral
VMD65Neutral
OM55Neutral
INGN52Neutral
SENS50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $600.58M | 25.53 | 10.73% | ― | 14.41% | 34.35% | |
| 66Neutral | $898.22M | 12.60 | 27.23% | ― | 3.87% | 623.68% | |
| 65Neutral | $347.48M | 22.52 | 10.78% | ― | 21.81% | 17.67% | |
| 55Neutral | $70.32M | -0.96 | -68.03% | ― | 1.58% | 70.22% | |
| 52Neutral | $147.95M | -4.34 | -20.06% | ― | -2.28% | -31.45% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $579.58M | -4.52 | -186.15% | ― | 104.83% | -37.15% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VMD | Viemed Healthcare US | 9.17 | 2.88 | 45.79% | |
| INGN | Inogen Inc | 5.69 | -1.02 | -15.20% | |
| SENS | Senseonics Holdings Inc. | 10.58 | 4.68 | 79.32% | |
| TCMD | Tactile Systems Technology | 26.81 | 3.37 | 14.38% | |
| OM | Outset Medical, Inc. | 3.73 | -1.19 | -24.19% | |
| BVS | Bioventus, Inc. | 10.66 | 3.60 | 50.99% |
Viemed Healthcare Corporate Events
Viemed Reports Record Third-Quarter Revenue and Profit Growth
PositiveOn November 4, 2026, Viemed reported record third-quarter net revenue of $80.7 million, up 12.2% year over year and 3.3% sequentially. Net income attributable to Viemed rose 32.0% year over year to $4.6 million, while Adjusted EBITDA increased 5.8% t...
Viemed Healthcare Updates Investor Deck, Highlights Growth Strategy
PositiveViemed Healthcare has released an updated investor deck dated August 2026, which it plans to use in presentations to investors, analysts and other stakeholders, and has made the materials available on its website. The presentation, framed as summary...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
